Iradimed (IRMD) Current Deferred Revenue (2013 - 2026)

Iradimed (IRMD) has 14 years of Current Deferred Revenue data on file, last reported at $7.2 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $7.2 million, up 23.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 million (up 23.34% YoY), and the FY2025 annual result was $2.9 million, down 45.35% from the prior year.
• Current Deferred Revenue grew to $7.2 million in Q1 2026 per IRMD's latest filing, from $2.9 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.2 million in Q1 2026 and troughed at $1.6 million in Q3 2022.
• A 5-year average of $3.1 million and a median of $2.6 million in 2023 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 148.03% in 2025 and fell as far as 45.35% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $3.4 million in 2022, then decreased by 23.8% to $2.6 million in 2023, then jumped by 104.36% to $5.3 million in 2024, then plunged by 45.35% to $2.9 million in 2025, then jumped by 149.18% to $7.2 million in 2026.
• Business Quant data shows IRMD's Current Deferred Revenue at $7.2 million in Q1 2026, $2.9 million in Q4 2025, and $3.2 million in Q3 2025.